局部芦可替尼治疗白癜风超应答的预测因素与临床影响:都灵白癜风登记处真实世界队列研究
该回顾性单中心队列研究纳入非节段性白癜风患者,评估局部芦可替尼1.5%乳膏单用或联合治疗的应答。约25%患者为超应答者,基线VSAS是超应答的唯一独立预测因素,超应答者基线疾病活动度与严重度更低、病程更短、肢端/远端受累更少。
要点
- 约25%患者为超应答者,各治疗组比例相似。
- 基线VSAS是超应答的唯一独立预测因素。
- 超应答者基线疾病活动度低、病程短、肢端受累少。
核心结论
- 局部芦可替尼治疗非节段性白癜风可产生进行性临床改善。
- 基线VSAS较低可识别更可能实现早期超应答的患者。
研究设计与样本
- 回顾性单中心队列研究,纳入非节段性白癜风患者。
- 患者接受局部芦可替尼1.5%乳膏单用或联合治疗。
- 评估时间点为基线、3个月(T1)和6个月(T2)。
- 超应答定义为T1时同时达到F-VASI75和T-VASI50。
主要发现
- 约25%患者为超应答者,各治疗组比例相似。
- 超应答者基线疾病活动度和严重度更低、病程更短、肢端/远端受累更少。
- 基线VSAS是超应答的唯一独立预测因素。
- 患者整体复色和疾病活动度进行性改善,面部病变应答更佳。
关键数值与推荐
- 超应答定义:T1时同时达到F-VASI75和T-VASI50。
临床怎么用
- 基线VSAS可用于识别更可能早期超应答的患者,辅助个体化治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Response to topical ruxolitinib in nonsegmental vitiligo is heterogeneous, and early predictors of repigmentation may help personalize treatment. OBJECTIVE: To identify baseline predictors of super-response to topical ruxolitinib 1.5% cream and evaluate the association between early and subsequent clinical outcomes. METHODS: We conducted a retrospective, single-center cohort study of patients with nonsegmental vitiligo treated with topical ruxolitinib 1.5% cream as monotherapy or in combination with concomitant therapies. Assessments were performed at baseline, 3 months (T1), and 6 months (T2). Super-responders were defined as patients achieving both F-VASI75 and T-VASI50 at T1. Baseline predictors were evaluated using multivariable logistic regression. RESULTS: Approximately 25% of patients were super-responders, with similar rates across treatment groups. Super-responders had lower baseline disease activity and severity, shorter disease duration, and less frequent acral/distal involvement. Baseline Vitiligo Signs of Activity Score (VSAS) was the only independent predictor of super-response. Overall, patients showed progressive improvement in repigmentation and disease activity, with greater responses in facial lesions. CONCLUSIONS: Topical ruxolitinib produced progressive clinical improvement. Lower baseline disease activity, measured by VSAS, identified patients more likely to achieve an early super-response and may help guide personalized treatment strategies.
引用
- Fiasconaro CA, Leo F, Cangialosi L, et al. Predictors and clinical impact of super-response in vitiligo patients treated with topical ruxolitinib: A real-world cohort study from a Turin Vitiligo Registry. J Am Acad Dermatol. 2026. PMID: 42665024. doi:10.1016/j.jaad.2026.08.091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。